ArticleBMC pulmonary medicine2017
Effects of treatment changes on asthma phenotype prevalence and airway neutrophil function.
Article in BMC pulmonary medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 22 citations in OpenAlex.
- Body Mass Index and Bronchodilator Responsiveness in Adults: Analysis of 2 Population-Based Studies in 4 South American Countries.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2025Article
- Association between Childhood Asthma Control Test scores and lung pathophysiologic indicators in longitudinal measurements.Journal of thoracic disease · 2023Article
- Phenotype overlap in the natural history of asthma.European respiratory review : an official journal of the European Respiratory Society · 2023Review
- Human PD-1 agonist treatment alleviates neutrophilic asthma by reprogramming T cells.The Journal of allergy and clinical immunology · 2023Article
- Which Therapy for Non-Type(T)2/T2-Low Asthma.Journal of personalized medicine · 2021Review
- Weighted gene co-expression network analysis to identify key modules and hub genes associated with paucigranulocytic asthma.BMC pulmonary medicine · 2021Article
- Enhanced airway sensory nerve reactivity in non-eosinophilic asthma.BMJ open respiratory research · 2021Article
- Review
- Understanding asthma phenotypes: the World Asthma Phenotypes (WASP) international collaboration.ERJ open research · 2018Article
- Non-eosinophilic asthma: current perspectives.Journal of asthma and allergy · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAsthma inflammatory phenotypes are often defined by relative cell counts of airway eosinophils/neutrophils. However, the importance of neutrophilia remains unclear, as does the effect of ICS treatment on asthma phenotypes and airway neutrophil function. The purpose of this study was to assess asthma phenotype prevalence/characteristics in a community setting, and, in a nested preliminary study, determine how treatment changes affect phenotype stability and inflammation, with particular focus on airway neutrophils.
methodsFifty adult asthmatics and 39 non-asthmatics were assessed using questionnaires, skin prick tests, spirometry, exhaled nitric oxide (FENO) measurement, and sputum induction. Twenty-one asthmatics underwent further assessment following treatment optimisation (n = 11) or sub-optimisation (n = 10).
resultsForty percent (20/50) had eosinophilic asthma (EA) and 8% had neutrophilic asthma. EA was associated with increased FENO, bronchodilator reversibility (BDR) and reduced lung function (p < 0.05). Following optimisation/sub-optimisation, the EA/NEA (non-eosinophilic asthma) phenotype changed in 11/21 (52%) asthmatics. In particular, fewer subjects had EA post treatment optimisation, but this was not statistically significant. However, a significant (p < 0.05) reduction in FENO, ACQ7 score, and BDR was observed after treatment optimisation, as well as an increase in FEV
conclusionsIn this community based population, non-eosinophilic asthma was common, less severe than EA, and at baseline most asthmatics showed no evidence of inflammation. In the nested change in treatment study, treatment optimisation was associated with reduced sputum eosinophils, improved symptoms and lung function, and enhanced neutrophil function, but a significant reduction in EA could not be demonstrated.
trial registrationThe nested change in treatment component of this study is registered at the Australia and New Zealand Clinical Trial Registry ( www.ANZCTR.org.au ) ACTRN12617001356358 . Registration date 27/09/2017. Retrospectively registered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.